CompletedPhase 2

Succinylated Gelatin for Prevention of Fluid Retention in Patients With Breast Cancer Receiving Docetaxel Chemotherapy

China216 participantsStarted 2019-09-01

Plain-language summary

Breast cancer patients who received docetaxel chemotherapy were randomly divided into two groups; experimental group: the patients received intravenous infusion of succinylated gelatin one day before and on the day of chemotherapy, 500ml each time, once per day; control group: observation. Primary endpoint: total incidence of fluid retention. Secondary endpoints: severity and duration of fluid retention, change in quality of life score.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed informed consent * Age ≥18 years * Diagnosed with breast cancer * ECOG 0-2 * Received chemotherapy with docetaxel Exclusion Criteria: * Existed peripheral edema, ascites and pleural or pericardial effusion * Serum creatinine exceeds 1.5 times of the upper normal limit * Total serum bilirubin exceeds 1.25 times of the upper normal limit, or ASAT exceeds 2 times of the upper normal limit

What they're measuring

Total incidence of fluid retention

Timeframe: 6 months

Trial details

NCT IDNCT04637308

SponsorGuangdong Provincial People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-09-30

View on ClinicalTrials.gov More Fluid Retention trials